Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MERCK & CO., INC.

(MRK)
  Report
Delayed Nyse  -  04:03:25 2023-01-30 pm EST
106.09 USD   +0.67%
12:25pAstraZeneca Doses First Patient in Phase 3 Study of Datopotamab Deruxtecan to Treat Lung Cancer
MT
11:36aDaiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatment
AN
09:24aMerck - FDA Approves KEYTRUDA as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients with Stage IB, II, or IIIA Non-Small Cell Lung Cancer
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Trending : Merck to Acquire Imago BioSciences for $1.35 Billion

11/21/2022 | 02:20pm EST

14:05 ET -- Merck & Co. Inc. is one of the most talked about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. Merck said it would acquire Imago BioSciences Inc. for $36 a share in cash for a total purchase price of about $1.35 billion. Imago is a clinical-stage biopharmaceutical company developing new medicines for myeloproliferative neoplasms and other bone marrow diseases. "This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology," said Robert Davis, Merck's president and chief executive officer. Dow Jones & Co. owns Factiva. (jennifer.tershak@wsj.com)


(END) Dow Jones Newswires

11-21-22 1420ET

Stocks mentioned in the article
ChangeLast1st jan.
MERCK & CO., INC. 0.67% 106.09 Delayed Quote.-5.02%
All news about MERCK & CO., INC.
12:25pAstraZeneca Doses First Patient in Phase 3 Study of Datopotamab Deruxtecan to Treat Lun..
MT
11:36aDaiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatment
AN
09:24aMerck - FDA Approves KEYTRUDA as Adjuvant Treatment Following Surgical Resection and Pl..
AQ
08:01aBerenberg Bank Adjusts Merck & Company Price Target to $125 From $115, Maintains Buy Ra..
MT
01/27Merck Says Keytruda Approved by FDA as Adjuvant Treatment for Non-Small Cell Lung Cance..
MT
01/27FDA Approves KEYTRUDA« (pembrolizumab) as Adjuvant Treatment Following Surgical Resecti..
BU
01/27Merck Announces the U.S. Food and Drug Administration has Approved KEYTRUDA
CI
01/26Merck & Co.'s Animal Health Unit Wins US FDA Nod for Expanded Use of Flea Drug for Dogs
MT
01/26Merck Animal Health Division Says US FDA Approves Expanded Indication of Bravecto Chews..
MT
01/26Merck Animal Health Receives U.S. FDA Approval of Expanded Indication for BRAVECTO (flu..
BU
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2022 59 128 M - -
Net income 2022 14 827 M - -
Net Debt 2022 17 475 M - -
P/E ratio 2022 18,1x
Yield 2022 2,63%
Capitalization 269 B 269 B -
EV / Sales 2022 4,84x
EV / Sales 2023 4,78x
Nbr of Employees 67 500
Free-Float 70,8%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 106,09 $
Average target price 116,78 $
Spread / Average Target 10,1%
EPS Revisions
Managers and Directors
Robert M. Davis Chairman & chief executive officer
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Dave Williams EVP, Chief Information & Digital Officer
Lisa LeCointe-Cephas Chief Ethics & Compliance Officer, SVP
Thomas Henry Glocer Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-5.02%267 180
JOHNSON & JOHNSON-4.77%439 835
ELI LILLY AND COMPANY-6.49%325 056
NOVO NORDISK A/S1.06%312 363
ROCHE HOLDING AG-0.40%277 685
ABBVIE INC.-9.49%258 606